Israeli officials on Saturday proposed creating an ad-hoc body to enable the voluntary migration of Palestinians from Gaza ...

AstraZeneca said on Friday it will spend Ksh.323 billion on a research and development hub in Beijing, as the drugmaker ...

In a bold move to cement its foothold in China’s booming biopharmaceutical sector, AstraZeneca announced Friday a $2.5 billion investment in Beijing over the next five years. The pharmaceutical titan ...

AstraZeneca has announced a $2.5 billion investment in a research and development hub in Beijing, underscoring its commitment ...

The pharma is spending $2.5 billion on an R&D center in Beijing. Elsewhere, Adaptimmune warned it could run out of cash and Pfizer sold its remaining stake in Haleon.

The largest of the collaborations is a potentially more than $4.68 billion partnership with Shanghai-based Harbour BioMed to discover and develop next-generation multi-specific antibodies for ...

AstraZeneca announced on Friday an investment of $2.5 billion in Beijing to establish the pharmaceutical company's sixth ...

BEIJING -- British pharmaceutical giant AstraZeneca signed a landmark $2.5-billion agreement on Friday to invest in Beijing ...

AstraZeneca plans to build a $2.5 billion research and development center in Beijing, the Britain-based multinational ...

AstraZeneca is further investing in China, opening an R&D center in Beijing and inking a pair of majorly backloaded R&D deals ...

Johnson & Johnson follows Eli Lilly in spending billions on U.S. manufacturing after President Donald Trump threatened major ...

The $2.5 billion investment reflects AstraZeneca's continued commitment to China, Chief Executive Pascal Soriot said. The R&D facility will be the company's second in China, coming after its research ...